Session Information
-
WCLC 2021
2021 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
All times listed are in Mountain Time MDT (UTC-6:00)
PL - Plenary
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
WS - Workshops
IS - Industry Symposium
MTE - Meet the Expert
BEDG - Brain Exchange Discussion Groups
September 8 Wed
Sep 8 Thursday
September 9 Thu
Sep 9 Friday
September 10 Fri
Sep 10 Saturday
September 11 Sat
Sep 11 Sunday
September 12 Sun
Sep 12 Monday
September 13 Mon
Sep 13 Tuesday
September 14 Tue
Sep 14
-
+
MA02 - RET and Novel Combinations of Osimertinib
- 09:30 - 10:30
- 9/08/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Novel Therapeutics and Targeted Therapies
-
+
MA02.04 - Discussant
09:45 - 10:00 | Presenter: Shengxiang (Harry) Ren
- Abstract
No abstract available for this presentation
-
+
P41 - Multimodality of Advanced Lung Cancer - Clinical Trials, Case Report
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Multimodality of Advanced Lung Cancer
-
+
P41.01 - Abscopal Response Induced by Thermal Ablation in Advanced NSCLC Patients Failed From Immunotherapy: Preliminary Result From a Phase 2 Trial
00:00 - 00:00 | Presenter: Chuchu Shao
- Abstract
Loading...
-
+
P66 - Small Cell Lung Cancer/ NET - Pre-Clinical
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Small Cell Lung Cancer/ NET
-
+
P66.06 - GPNMB Associates With Inferior Prognosis in SCLC Patients Through Promoting Tumor Cell Metastasis
00:00 - 00:00 | Presenter: qian liu
- Abstract
Loading...
-
+
MA13 - Building on the Past: What Will Be the Next Immunotherapy Combination?
- 17:30 - 18:30
- 9/13/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Immunotherapy (Phase II/III Trials)
-
+
MA13.01 - Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Non-Squamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
17:30 - 17:35 | Presenter: Shengxiang (Harry) Ren
- Abstract
Loading...
